News

Biofuels producers join forces
Enlarge image

PolicyBelgiumEUGermanyItalyUKFinland

Biofuels producers join forces

11.02.2013 - Seven leading producers of second generation biofuels have joined forces in an industry initiative to support uptake of their technology.

The initiative, named “Leaders of Sustainable Biofuels”, aims at supporting the development of second generation biofuels as a sustainable alternative to fossil fuels in Europe. The leaders of Chemtex, British Airways, BTG, Chemrec, Clariant, Dong Energy and UPM are joining forces to ensure the market uptake of advanced sustainable biofuels by all transport sectors. The Chief Executive Officers of the companies suggested biofuels were cost-competitive and had less environmental impact than fuels made from oil or natural gas. They argue that second-generation biofuels can reduce GHG emissions by at least 65%.

In contrast, first generation biofuels, made from corn, wheat, soy or palm provide only modest reductions in greenhouse gases and can push up food prices. At the initiative’s launch in Brussels, the “Leaders of Sustainable Biofuels” demanded to accelerate research and innovation into emerging biofuel technologies, including algae and new conversion pathways, supported by public and private R&D programmes. They said it were important to develop worldwide accepted sustainability certification and to establish financing structures to facilitate the implementation of sustainable biofuel projects. The initiative aims at promoting the benefits of advanced sustainable biofuels and to address national policy makers, the European Commission and the European Parliament. The “Leaders are convinced that their biofuels are key for the reduction of fossil energy imports in the EU”. 

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/biofuels-producers-join-forces.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • EVOCUTIS (UK)0.18 GBP-10.00%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%

TOP

  • KARO BIO (S)38.10 SEK2311.4%
  • TRANSGENE (F)5.08 EUR78.2%
  • BIOTECH PHARMACON (N)12.60 NOK33.1%

FLOP

  • THROMBOGENICS (B)2.90 EUR-43.0%
  • WILEX (D)2.05 EUR-37.5%
  • BIONOR PHARMA (N)1.28 NOK-37.3%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.93 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 28.08.2015